Zydus Cadila receives US FDA nod for anti-bacterial drug doxycycline
The company will commence supplies to the US market from its formulation manufacturing facility at SEZ in Ahmedabad
Zydus Cadila yesterday received approval from US FDA to market doxycycline capsules (50 mg, 75 mg and 100 mg), an anti-bacterial drug. With this first approval, the group will now commence supplies to the US market from its formulation facility located at the SEZ in Ahmedabad.
The group now has 102 approvals and has so far filed over 280 ANDAs since the commencement of the filing process in FY 2003-04.
The group now has 102 approvals and has so far filed over 280 ANDAs since the commencement of the filing process in FY 2003-04.